The 480,000 square-foot facility will put all our cross-functional experts in the Bay Area under one roof, opening up more opportunities for collaboration and innovation in oncology research and development.
“Today, our scientists and colleagues in South San Francisco are exploring new frontiers in exciting areas – like immuno-oncology, tumor targeting, tumor dependencies and precision medicine – and finding new approaches that we hope will change how we treat cancer and other diseases in the future,” said Tom Hudson, senior vice president of R&D and chief scientific officer, AbbVie.
In addition to the nearly 1,000 full-time employees already employed at our campus, we continue to hire across a wide range of R&D disciplines, including drug discovery research, oncology early development, precision medicine, regulatory affairs, clinical trial management and medical affairs, among many others.
“As we officially launch this new facility, we are showcasing our leadership of being a great place to work in the Bay Area and California, while also helping to create jobs that fuel the biotech industry and the local economy,” said Mo Trikha, vice president and head of oncology early development, Bay Area site head, AbbVie.
Advancing research partnerships in San Francisco
Along with bringing internal teams closer together, our new location puts us in close proximity to other life science companies, a number of whom we partner with today. This makes it easier for our dedicated and experienced teams to join forces with outside partners that complement our strengths, capabilities and commitment to oncology.
“One thing we know is that solving some of the toughest challenges in medicine requires bringing together diverse minds and areas of expertise – and proximity makes it easier for us to work together to advance science,” said Trikha.